Back to results
US 2026/0258025 A1Published application
Inhibitors of tdp-43 and tau aggregation
AssigneeAquinnah Pharmaceuticals, Inc.
InventorJoseph P. Vacca
Life of this patent
Estimating the term…
Abstract
Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.
Claims101
A compound of Formula (I):
- or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
- E is C3-C7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, and E may be optionally substituted;
- E′ is absent, or E′ is C3-C7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, and E′ may be optionally substituted;
- and
- R3x and R4 are each H or an independently selected optional substituent.
2 more elements
A compound of Formula (II):
- or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
- Z1 is N or CR11;
- Z2 is N or CR12;
- Z3 is N or CR13;
- Z4 is N or CR14;
- L1 is absent, or L2 is C1-C6 alkylene, C1-C6 heteroalkylene, —O—, —S—, or —NR′—, wherein the C1-C6 alkylene and C1-C6 heteroalkylene are optionally substituted;
- A is H, halo, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, and A may be optionally substituted;
- or A and R11 are taken together with the atoms to which they are attached to form an optionally substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbocyclic, or heterocyclic ring;
- R11, R12, R13, and R14 are each independently H or an optional substituent;
- each R′ is H or C1-C6 alkyl;
- and
- each of R3x and R4 is independently H or an independently selected optional substituent,
- wherein no more than two of Z1, Z2, Z3 and Z4 are N.
10 more elements
A compound of Formula (II):
- or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
- Z1 is N or CR11;
- Z2 is N or CR12;
- Z3 is N or CR13;
- Z4 is N or CR14;
- L1 is absent, or L1 is C1-C6 alkylene, C1-C6 heteroalkylene, —O—, —S—, or —NR′—, wherein the C1-C6 alkylene and C1-C6 heteroalkylene are optionally substituted by 1-4 independently substituents selected from ═O (oxo), OH, and halogen;
- A is H, halo, C1-C10 alkyl, C1-C10 heteroalkyl, C1-C6 haloalkyl, C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, C6-C10 aryl, 5-6 membered heteroaryl, C6-C10 carbocyclyl, or -5-10 membered heterocyclic ring, and A is substituted by one R1 group and optionally substituted by 1-4 independently selected R2 groups;
- or A and R11 are taken together with the atoms to which they are attached to form a C3-C7 cycloalkyl, aryl, 5-6 membered heteroaryl, or 3-7 membered heterocyclic ring, wherein the heteroaryl and heterocyclyl have 1-3 ring heteroatoms selected from N, O, and S, and wherein each of the rings is optionally substituted by one R1 group and optionally substituted by 1-4 independently selected R2 groups;
- each of R11, R12, R13, and R14 is independently H or R3;
- R1 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C9 heteroalkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, —NH2, or -L2-G, wherein the C1-C6 alkyl may be optionally substituted with OH, and wherein the C1-C6 heteroalkyl may be optionally substituted with C2-C6 heteroalkynyl;
- L2 is absent, or L2 is C1-C6 alkylene, C1-C6 heteroalkylene, —O—, —S—, or —NR′—, wherein the C1-C6 alkylene and C1-C6 heteroalkylene are optionally substituted by 1-4 substituents independently selected from ═O (oxo), OH, and halogen;
- G is C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, aryl, 5-6 membered heteroaryl, 6-10 membered carbocyclyl, or 5-10 membered heterocyclyl, wherein the 3-7 membered heterocycloalkyl, 5-6 membered heteroaryl, and 5-10 membered heterocyclyl have 1-3 ring heteroatoms selected from N, O, and S, and wherein G may be optionally substituted by 1-4 RA substituents;
- each RA is independently selected from the group consisting of C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, ═O (oxo), OH, —NMe2, —NHMe, —NH2, CN, and halo;
- each R2 is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, ═O (oxo), —OH, —NMe2, —NHMe, —NH2, and halo;
- each R3 is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, OH, cyano, and halo;
- R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, cyano, and halo;
- each R′ is H or C1-C6 alkyl;
- and
- R3x is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo,
- wherein no more than two of Z1, Z2, Z3 and Z4 are N.
17 more elements
A compound of Formula (III):
- or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
- X1 is NR1, O, S, SO2, CH2, or CHR1;
- X2 is N or CH;
- R1 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, —NH2, and -L2-G, wherein the C1-C6 alkyl may be optionally substituted with one or more OH, and wherein the C1-C6 heteroalkyl may be optionally substituted with C2-C6 heteroalkynyl;
- L2 is absent, or L2 is selected from the group consisting of C1-C6 alkylene, C1-C6 heteroalkylene, —O—, —S—, and —NR′—, wherein the C1-C6 alkylene and C1-C6 heteroalkylene are optionally substituted by 1-4 substituents independently selected from the group consisting of ═O (oxo), OH, and halogen;
- G is selected from the group consisting of C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, aryl, 5-6 membered heteroaryl, 6-10 membered carbocyclyl, and 5-10 membered heterocyclyl, wherein the 3-7 membered heterocycloalkyl, 5-6 membered heteroaryl, and 5-10 membered heterocyclyl have 1-3 ring heteroatoms selected from N, O, and S, and wherein G may be optionally substituted by 1-4 RA substituents;
- each RA is independently selected from the group consisting of C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, OH, CN, and halo;
- each R2 is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, —NH2, and halo;
- each R3 is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, OH, cyano, and halo;
- R3x is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo;
- R4 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C9 heteroalkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, cyano, and halo;
- each R′ is H or C1-C6 alkyl;
- m is 0 or 1;
- n is 0 or 1;
- p is 0, 1, 2, 3, or 4;
- and
- g is 0, 1, 2, 3, or 4.
14 more elements
A compound of Formula (III):
- or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
- X1 is selected from the group consisting of NR1, O, S, SO2, CH2, and CHR1;
- X2 is N or CH;
- R1 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, —NH2, and -G;
- G is selected from the group consisting of C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, aryl, 5-6 membered heteroaryl, 6-10 membered carbocyclyl, and 5-10 membered heterocyclyl, wherein the 3-7 membered heterocycloalkyl, 5-6 membered heteroaryl, and 5-10 membered heterocyclyl have 1-3 ring heteroatoms selected from N, O, and S, and wherein G may be optionally substituted by 1-4 RA substituents;
- each RA is independently selected from the group consisting of C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, OH, CN, and halo;
- each R2 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, and halo;
- each R3 is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo;
- R3x is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo;
- R4 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, cyano, and halo;
- m is 0 or 1;
- n is 0 or 1;
- p is 0, 1, 2, 3, or 4;
- and
- q is 0, 1, 2, 3, or 4.
12 more elements
A compound of Formula (IV):
- or stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein:
- Z1 is N or CR11;
- Z2 is N or CR12;
- Z3 is N or CR13;
- Z4 is N or CH;
- R11 is selected from the group consisting of H, —OH, halo, C1-C6 alkyl, C1-C6 heteroalkyl, and C1-C6 haloalkoxy;
- R12 is selected from the group consisting of H, —OH, halo, C1-C6 alkyl, C1-C6 heteroalkyl, and C1-C6 haloalkoxy;
- R13 is H or halo;
- R14 is selected from the group consisting of H, halo, C1-C6 alkylene, C1-C6 heteroalkylene, 5-7 membered aryl, 5-7 membered heteroaryl, and 3-7 membered heterocycloalkyl, wherein the R14 may be optionally substituted with one or more R14a;
- R14a is selected from the group consisting of C1-C6 alkyl, C1-C6 heteroalkyl, C3-C7 cycloalkyl, 5-7 membered aryl, 3-7 membered heterocycloalkyl, and —C(O)OR14b, wherein the C1-C6 alkyl or the 3-7 membered heterocycloalkyl may be optionally substituted with one or more R14b;
- R14b is selected from the group consisting of —OH, oxo, C1-C6 alkyl, C1-C5 heteroalkyl, C2-C6 alkynyl, and 3-7 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl may be optionally substituted with one or more C1-C6 alkyl;
- wherein when Z2 is CR12, R12 and R14 may be taken together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, or aryl, wherein the cycloalkyl or the heterocycloalkyl may be optionally substituted with one or more C1-C6 alkyl or C1-C6 heteroalkyl;
- R3x is H or C1-C6 alkyl;
- and
- R4 is selected from the group consisting of H, halo, C1-C6 alkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, and C1-C6 haloalkoxy.
12 more elements
A compound selected from any compound set forth in Table 1, or stereoisomer and/or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.